Does Virtual Reality Improve Symptom Burden in Dialysis Patients?
Launched by DAVID BLUM · Jan 31, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring whether virtual reality (VR) therapy can help reduce symptoms and improve mental wellbeing for patients undergoing dialysis. During the study, participants will experience a 30-minute VR session while receiving their regular hemodialysis treatment, which happens three times a week. The trial aims to find out if using VR can make dialysis patients feel better both physically and mentally over the course of one month.
To participate in this study, individuals need to be at least 18 years old and currently receiving hemodialysis for three to five hours at a time. They should not have any serious visual or hearing impairments and must be able to understand and speak either German or English. It’s also important that they do not have cognitive impairments and can provide informed consent. However, individuals with epilepsy or who are currently pregnant cannot take part in the trial. This study will give patients a chance to see if virtual reality can be a helpful tool during their dialysis sessions.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Older than 18 years;
- • in treatment with thrice-weekly hemodialysis sessions;
- • regular hemodialysis duration of three to five hours
- • having no visual impairment
- • having no acoustic deficit
- • patient must be capable of speaking and understanding German or English
- • no signs of cognitive impairment
- • patient oriented in time and space
- • being able to give informed consent as documented by signature
- Exclusion Criteria:
- • diagnosis of epilepsy
- • current pregnancy
About David Blum
David Blum is a distinguished clinical trial sponsor with extensive experience in the design, management, and execution of clinical research studies. Committed to advancing medical science and improving patient outcomes, Mr. Blum collaborates with leading healthcare professionals and institutions to facilitate innovative trials across various therapeutic areas. His strategic approach emphasizes rigorous adherence to regulatory standards, ethical considerations, and data integrity, ensuring that each study contributes valuable insights to the medical community. With a strong focus on fostering partnerships and enhancing participant engagement, David Blum is dedicated to driving progress in clinical research and transforming healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Zürich, Zh, Switzerland
Patients applied
Trial Officials
David Blum, Prof. Dr.
Principal Investigator
University of Zurich
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported